Bruker's CEO Presents At Barclays Capital Global Healthcare Conference (Transcript)

Bruker Corporation ( BRKR)

Barclays Capital Global Healthcare Conference Call

March 14, 2012 3:45 pm ET


Frank H. Laukien – Chairman, President and Chief Executive Officer


Christina Zhang – Barclays Capital


Christina Zhang – Barclays Capital

Hi, good afternoon and welcome to the second day of the Global Barclays Healthcare Conference. My name is Christina Zhang and I am the biopharma analyst here at Barclays. And here with us is Dr. Frank Laukien from Bruker Corporation.

Frank H. Laukien

Thanks very much, Christina. And we are now in the double-digit, so I appreciate that very much. Thank you very much for joining us this afternoon.

I'd like to point out my colleague, Stacey Desrocher, our Investor Relations Officer; she's also our Treasurer. So I need discerning questions about leverage, hedging, our balance sheet, cash flow, will all be answered by Stacey.

Let me take you through some of the highlights of what we're doing at Bruker. One thing that I'd like to point out that's not in this presentation yet, we just had a press conference at the Pittsburgh Conference or PITTCON yesterday, where we introduced several new products, including some systems for FT-IR for Hyperspectral Imaging, a number of important products. I wouldn't call them game changers, but solid products, very unique competitive profiles, and I think also very good margins.

So please refer to our website, to our latest press releases. There was quite a bit of Bruker innovation coming out at PITTCON. And yesterday we presented it to a non-financial audience of science editors and hopefully they'll write lots of great articles about it.

If you liked this article you might like

Insiders Load Up on AIG, Anadarko and More

Analysts' Actions -- Bruker, Endologix, Mosaic, Trex and More

Ex-Dividends To Watch: 3 Stocks Going Ex-Dividend Tomorrow: GBDC, DW, BRKR

Don't Miss Today's Strong And Under The Radar Stock: Bruker (BRKR)

Bruker (BRKR) Stock Closed Down on Leerink Downgrade